Patents by Inventor John McKearn

John McKearn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11459307
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: October 4, 2022
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS
    Publication number: 20220251191
    Abstract: Provided are compositions and methods for treating cancer by administering antiCD47 mAbs and anti-CD47 fusion proteins with distinct functional profiles or chimeric antigen receptor (CAR)-bearing immune effector cells in combination with analogs of interleukin proteins.
    Type: Application
    Filed: November 16, 2021
    Publication date: August 11, 2022
    Inventors: James BLINN, John MCKEARN, Joseph MONAHAN, William R. STROHL, Robyn PURO, John RICHARDS, Daniel S. PEREIRA, Juan C. ALMAGRO
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20210198216
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: August 12, 2020
    Publication date: July 1, 2021
    Inventors: John M. MCCALL, Donna L. ROMERO, John MCKEARN, Michael CLARE
  • CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
    Publication number: 20210085625
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Inventors: John MCKEARN, Jeremy BLITZER
  • Controlled release oral pharmaceutical dosage forms comprising MGBG
    Patent number: 10881626
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: January 5, 2021
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 10781185
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 22, 2020
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
    Publication number: 20200147137
    Abstract: Disclosed herein are transmembrane proteins comprising at least two chains, each chain comprising an endodomain, a transmembrane domain, and an ectodomain; wherein the ectodomains of the at least two chains of the transmembrane protein interact together to bind to a drug or soluble protein; wherein the endodomains of the at least two chains of the transmembrane protein together comprise a structure functionally similar to that of an IL-2 receptor endodomain, an IL-7 receptor endodomain, or an IL-15 receptor endodomain; and wherein binding of the drug or soluble protein to the ectodomain activates IL-2, IL-7, or IL-15 signaling in CAR-bearing immune effector cells.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 14, 2020
    Inventors: John MCKEARN, Ayman KABAKIBI, You W. ZHOU
  • METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING
    Publication number: 20190224144
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Application
    Filed: April 1, 2019
    Publication date: July 25, 2019
    Inventors: John MCKEARN, Jeremy BLITZER
  • Methods and compositions for treatment of demyelinating diseases
    Patent number: 10350178
    Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
    Patent number: 10292950
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 21, 2019
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING
    Publication number: 20180369170
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Application
    Filed: May 12, 2017
    Publication date: December 27, 2018
    Inventors: John MCKEARN, Jeremy BLITZER
  • METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20180360783
    Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Inventors: Jeremy BLITZER, John MCKEARN
  • Methods and compositions for treatment of demyelinating diseases
    Patent number: 10085955
    Abstract: Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 2, 2018
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20180230108
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: December 6, 2017
    Publication date: August 16, 2018
    Inventors: John M. MCCALL, Donna L. ROMERO, John MCKEARN, Michael CLARE
  • CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
    Publication number: 20180050000
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Application
    Filed: May 1, 2017
    Publication date: February 22, 2018
    Inventors: John MCKEARN, Jeremy BLITZER
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9868708
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 16, 2018
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
    Publication number: 20170290788
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Application
    Filed: February 23, 2017
    Publication date: October 12, 2017
    Inventors: John MCKEARN, Jeremy BLITZER
  • Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
    Patent number: 9675566
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 13, 2017
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Controlled release oral pharmaceutical dosage forms comprising MGBG
    Patent number: 9668988
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 6, 2017
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
    Patent number: 9616035
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: April 11, 2017
    Assignee: PATHOLOGICA, LLC
    Inventors: John McKearn, Jeremy Blitzer